Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

PurposeDifferentiating lymph node metastases (LNM) from peripheral ganglia by physiological prostate-specific membrane antigen (PSMA) uptake is challenging. Two tracers (68Ga-PSMA-11 and 18F-fluorodeoxyglucose [FDG]) metabolic uptake patterns were evaluated by positron emission tomography-computed t...

Full description

Bibliographic Details
Main Authors:	Yiping Shi, Lian Xu, Yinjie Zhu, Yining Wang, Ruohua Chen, Jianjun Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Oncology
Subjects:	68Ga-PSMA-11 18F-FDG ganglia lymph node metastases prostate cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.646110/full

Similar Items

The Heterogeneous Metabolic Patterns of Ganglia in 68Ga-PSMA, 11C-choline, and 18F-FDG PET/CT in Prostate Cancer Patients
by: Yiping Shi, et al.
Published: (2021-04-01)

Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
by: Conrad Leitsmann, et al.
Published: (2021-03-01)

Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
by: Medhat M. Osman, et al.
Published: (2021-04-01)

The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using 68Ga-PSMA PET/CT as References
by: Jianhua Jiao, et al.
Published: (2021-04-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0
by: Jonathan Kuten, et al.
Published: (2021-01-01)

The “question-mark” MR anatomy of the cervico-thoracic ganglia complex: can it help to avoid mistaking it for a malignant lesion on 68Ga-PSMA-11 PET/MR?
by: Bialek Ewa J., et al.
Published: (2019-10-01)

Optimization of injected 68Ga-PSMA activity based on list-mode phantom data and clinical validation
by: J. Wielaard, et al.
Published: (2020-04-01)

What to Trust, PSA or [68Ga]Ga-PSMA-11: Learn from Experience
by: Viglialoro R, et al.
Published: (2021-08-01)

Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11
by: Nicole N. Waterhouse, et al.
Published: (2020-02-01)

Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
by: Melissa E. Rodnick, et al.
Published: (2020-11-01)

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
by: Zohar Keidar, et al.
Published: (2018-11-01)

Solitary Internal Mammary Lymph Node Metastases Detected by18F-FDG-PET/CT in Ovarian Cancer
by: Alessandra Bernardi, et al.
Published: (2011-02-01)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020-11-01)

Estudo de radiomarcação com gálio-68 do inibidor de PSMA baseado em ureia - avaliação comparativa de método automatizado e não automatizado
by: Alcarde, Lais Fernanda
Published: (2016)

Estudo de radiomarcação com gálio-68 do inibidor de PSMA baseado em ureia - avaliação comparativa de método automatizado e não automatizado
by: Lais Fernanda Alcarde
Published: (2016)

Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach
by: Alberto Miceli, et al.
Published: (2021-09-01)

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
by: Amir Iravani, et al.
Published: (2017-12-01)

Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
by: Kristina Sandgren, et al.
Published: (2019-01-01)

The diagnostic value of PET/CT imaging with the 68Ga-labeled PSMA-ligand in the follow up assessment of prostate cancer after therapy
by: Talaat Ahmed Abd El Hameed Hassan, et al.
Published: (2020-07-01)

Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
by: Jing Zhao, et al.
Published: (2020-12-01)

High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation
by: Labib Ataur Rahman, et al.
Published: (2019-12-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
by: Helge Thisgaard, et al.
Published: (2021-01-01)

Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients
by: Florian Rosar, et al.
Published: (2020-05-01)

Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients
by: Thomas Ebenhan, et al.
Published: (2015-08-01)

Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis
by: Garba Haruna Yunusa, et al.
Published: (2021-07-01)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
by: Stefan A. Koerber, et al.
Published: (2021-03-01)

Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT
by: Fadi Khreish, et al.
Published: (2021-08-01)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
by: Stephen McGeorge, et al.
Published: (2021-09-01)

68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy
by: Mikhail Kesler, et al.
Published: (2021-02-01)

The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
by: Kai Shen, et al.
Published: (2021-07-01)

Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
by: Qing Zhang, et al.
Published: (2017-11-01)

Competition (‘Steal’ Phenomenon) between [<sup>68</sup>Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue
by: Esmée C. A. van der Sar, et al.
Published: (2021-05-01)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
by: Nat P. Lenzo, et al.
Published: (2018-02-01)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
by: Vikas Prasad, et al.
Published: (2021-03-01)

[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study
by: Sebastian Hoberück, et al.
Published: (2020-11-01)

Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
by: Matthias Eder, et al.
Published: (2014-06-01)

Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report
by: Letjie C. Maserumule, et al.
Published: (2021-03-01)

Inguino-scrotal bladder hernia: an unexpected finding on 68Ga-PSMA PET/CT
by: Shirin Shahlaei, et al.
Published: (2020-07-01)